Kura Oncology, Inc. — 2022 Q1 Form 10-Q Summary
Business context and reporting period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its principal programs are ziftomenib for genetically defined acute myeloid leukemia, tipifarnib for HRAS-mutant head and neck squamous cell carcinoma and other indications, and preclinical candidate KO-2806. The filing covers the three months ended March 31, 2022; financial statements are unaudited and presented under U.S. GAAP.
Financial condition and key metrics
- Revenue: None from product sales; the company has no approved products.
- Operating expenses: $32.8 million, up from $30.9 million in Q1 2021. Research and development was $20.9 million, up 2.9%; general and administrative expense was $11.9 million, up 12.3%.
- Net loss: $32.5 million, compared with $30.7 million in Q1 2021. Basic and diluted net loss was $0.49 per share versus $0.46.
- Comprehensive loss: $37.3 million, including a $4.9 million unrealized loss on marketable securities and foreign currency.
- Cash flow: Net cash used in operating activities was $32.2 million, compared with $28.5 million in Q1 2021. Investing cash use was $25.0 million, primarily reflecting purchases of marketable securities. Financing activities provided $0.3 million.
- Liquidity: Cash, cash equivalents and short-term investments totaled $480.1 million at March 31, 2022, consisting of $33.8 million of cash and cash equivalents and $446.2 million of short-term investments. Management expects existing liquidity to fund operating and capital requirements through 2024 based on current plans.
- Debt and liabilities: Total liabilities were $22.3 million, including $6.4 million of operating lease liabilities. The filing reports no interest-bearing debt outstanding at March 31, 2022.
- Equity and dilution: Common shares outstanding were 66.6 million at March 31, 2022. Share-based compensation expense was $6.7 million, compared with $5.1 million in Q1 2021.
Material changes versus the prior comparable period
- Net loss increased by $1.8 million, primarily due to higher operating expenses.
- Ziftomenib-related research and development costs increased $1.4 million to $4.1 million as clinical-trial activity expanded.
- Tipifarnib-related research and development costs decreased $5.3 million to $4.9 million, primarily due to lower manufacturing, companion-diagnostic and clinical costs.
- Personnel and other research and development costs increased $2.8 million, and research and development share-based compensation increased $1.1 million.
- General and administrative expense increased $1.3 million, primarily due to higher professional fees and non-cash share-based compensation.
- Operating cash use increased $3.7 million. Investing cash use declined substantially from $186.2 million to $25.0 million because the company purchased fewer marketable securities than in Q1 2021.
- Unrealized losses on available-for-sale securities increased materially, primarily because of interest-rate changes rather than identified credit losses. The company reported no allowance for credit losses.
Guidance, outlook, commentary and risks
- The company completed enrollment in the Phase 1b expansion cohorts of KOMET-001 and expected to identify the recommended Phase 2 dose and report top-line ziftomenib data in the third quarter of 2022.
- The FDA lifted the partial clinical hold on KOMET-001 in January 2022 after agreement on a mitigation strategy for differentiation syndrome. The hold had followed a Grade 5 serious adverse event potentially associated with differentiation syndrome.
- Kura expected to dose the first patient in the KURRENT-LUNG Phase 1 trial of tipifarnib plus osimertinib in the third quarter of 2022 and expected to submit a KO-2806 IND in the fourth quarter of 2022.
- The AIM-HN registration-directed trial of tipifarnib was subject to enrollment delays related to COVID-19 and protocol changes; the company stated that it could not reasonably forecast when the trial would be fully enrolled.
- In February 2022, Kura replaced its unused $75.0 million sales agreement with a new ATM facility permitting sales of up to $150.0 million of common stock. No shares had been sold under the new facility as of the filing date.
- The company expects continuing losses and increasing research and development expenses and will require substantial additional financing. No committed external funding source was available; future equity financing could dilute stockholders.
- Key risks include clinical-trial failure or delay, serious adverse events, regulatory holds or non-approval, difficulty enrolling biomarker-defined patients, dependence on third-party manufacturers and CROs, companion-diagnostic development, COVID-19-related disruptions, intellectual-property challenges, competition and future capital needs.
- Kura reported no material legal proceedings and concluded that its disclosure controls and procedures were effective as of March 31, 2022.
Most important facts for investors to verify
- Whether KOMET-001 ziftomenib data and recommended-dose timing met the stated third-quarter 2022 expectations, including differentiation-syndrome safety mitigation.
- Actual quarterly cash burn and whether the projected liquidity runway through 2024 remains supportable as clinical programs expand.
- Whether Kura has drawn on the $150.0 million ATM facility or otherwise issued additional equity, and the resulting dilution.
- Enrollment progress, trial design and regulatory status of AIM-HN and KURRENT-HN.
- Regulatory and clinical progress for KO-2806, including the planned IND submission.
- Changes in unrealized investment losses, interest rates and the composition and maturity of the short-term investment portfolio.
- Whether additional financing, collaboration or licensing transactions become necessary before product revenue is available.